{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:15:48Z","timestamp":1790867748580,"version":"4.1.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/qai.0b013e3181b880f3","type":"journal-article","created":{"date-parts":[[2009,11,4]],"date-time":"2009-11-04T08:14:56Z","timestamp":1257322496000},"page":"433-442","source":"Crossref","is-referenced-by-count":24,"title":["Tonsillar Application of AT-2 SIV Affords Partial Protection Against Rectal Challenge With SIVmac239"],"prefix":"10.1097","volume":"52","author":[{"given":"Panagiotis","family":"Vagenas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vennansha G","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Piatak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian W","family":"Bess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D","family":"Lifson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agegnehu","family":"Gettie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Robbiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210131","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1056\/NEJMp0708117","article-title":"One step forward, two steps back-will there ever be an AIDS vaccine?","volume":"357","author":"Steinbrook","year":"2007","journal-title":"N Engl J Med"},{"key":"R2-1-20210131","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1126\/science.1152622","article-title":"Toward an AIDS vaccine.","volume":"320","author":"Walker","year":"2008","journal-title":"Science"},{"key":"R3-1-20210131","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1146\/annurev.iy.08.040190.003013","article-title":"The simian immunodeficiency viruses.","volume":"8","author":"Desrosiers","year":"1990","journal-title":"Ann Rev Immunol"},{"key":"R4-1-20210131","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/IAI.59.4.1465-1469.1991","article-title":"Induction of antibody response to Chlamydia trachomatis in the genital tract by oral immunization.","volume":"59","author":"Cui","year":"1991","journal-title":"Infect Immun"},{"key":"R5-1-20210131","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1128\/IAI.64.12.5341-5348.1996","article-title":"Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge.","volume":"64","author":"Pal","year":"1996","journal-title":"Infect Immun"},{"key":"R6-1-20210131","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/infdis\/168.3.622","article-title":"Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B.","volume":"168","author":"Gallichan","year":"1993","journal-title":"J Infect Dis"},{"key":"R7-1-20210131","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.virol.2003.10.010","article-title":"Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa.","volume":"318","author":"Milligan","year":"2004","journal-title":"Virology"},{"key":"R8-1-20210131","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1084\/jem.184.5.1879","article-title":"Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization.","volume":"184","author":"Gallichan","year":"1996","journal-title":"J Exp Med"},{"key":"R9-1-20210131","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/515286","article-title":"Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization.","volume":"177","author":"Gallichan","year":"1998","journal-title":"J Infect Dis"},{"key":"R10-1-20210131","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/344232","article-title":"Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.","volume":"186","author":"Dumais","year":"2002","journal-title":"J Infect Dis"},{"key":"R11-1-20210131","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1189\/jlb.1007675","article-title":"Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection.","volume":"83","author":"Adalid-Peralta","year":"2008","journal-title":"J Leukoc Biol"},{"key":"R12-1-20210131","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1089\/aid.2004.20.1269","article-title":"Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations.","volume":"20","author":"Vajdy","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R13-1-20210131","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1089\/0889222041725253","article-title":"An SHIV DNA\/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.","volume":"20","author":"Wang","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R14-1-20210131","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1016\/j.vaccine.2006.06.050","article-title":"Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV.","volume":"24","author":"Pahar","year":"2006","journal-title":"Vaccine"},{"key":"R15-1-20210131","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.virol.2008.09.016","article-title":"Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.","volume":"382","author":"Bogers","year":"2008","journal-title":"Virology"},{"key":"R16-1-20210131","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.virol.2008.10.012","article-title":"Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques.","volume":"383","author":"Schulte","year":"2009","journal-title":"Virology"},{"key":"R17-1-20210131","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/JVI.01672-08","article-title":"Correlation of vaccine-elicited systemic and mucosal non-neutralizing antibody activities with reduced acute viremia following intrarectal SIVmac251 challenge of rhesus macaques.","volume":"83","author":"Hidajat","year":"2009","journal-title":"J Virol"},{"key":"R18-1-20210131","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1034\/j.1600-0684.2002.02007.x","article-title":"Whole inactivated SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity, and activity against intrarectal challenge.","volume":"31","author":"Lifson","year":"2002","journal-title":"J Med Primatol"},{"key":"R19-1-20210131","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1128\/JVI.76.6.2936-2951.2002","article-title":"Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs.","volume":"76","author":"Frank","year":"2002","journal-title":"J Virol"},{"key":"R20-1-20210131","first-page":"7","article-title":"Presentation of exogenous whole inactivated simian immunodeficiency virus by mature dendritic cells induces CD4+ and CD8+ T cell responses.","volume":"34","author":"Frank","year":"2003","journal-title":"J AIDS"},{"key":"R21-1-20210131","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm806","article-title":"Therapeutic dendritic-cell vaccine for simian AIDS.","volume":"9","author":"Lu","year":"2003","journal-title":"Nat Med"},{"key":"R22-1-20210131","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1147","article-title":"Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.","volume":"10","author":"Lu","year":"2004","journal-title":"Nat Med"},{"key":"R23-1-20210131","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/eji.200324032","article-title":"Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.","volume":"34","author":"Vollmer","year":"2004","journal-title":"Eur J Immunol"},{"key":"R24-1-20210131","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1189\/jlb.1202630","article-title":"Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions.","volume":"73","author":"Marshall","year":"2003","journal-title":"J Leuk Biol"},{"key":"R25-1-20210131","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.4049\/jimmunol.173.3.1647","article-title":"CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells.","volume":"173","author":"Teleshova","year":"2004","journal-title":"J Immunol"},{"key":"R26-1-20210131","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1189\/jlb.0205084","article-title":"CpG-C ISS-ODN activation of blood-derived B cells from healthy and chronic immunodeficiency virus-infected macaques.","volume":"79","author":"Teleshova","year":"2006","journal-title":"J Leuk Biol"},{"key":"R27-1-20210131","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.4049\/jimmunol.177.12.8531","article-title":"Local and systemic effects of intranodally injected CpG-C ISS-ODNs in macaques.","volume":"177","author":"Teleshova","year":"2006","journal-title":"J Immunol"},{"key":"R28-1-20210131","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.4049\/jimmunol.168.4.1659","article-title":"CpG oligodeoxynucleotides as vaccine adjuvants in primates.","volume":"168","author":"Verthelyi","year":"2002","journal-title":"J Immunol"},{"key":"R29-1-20210131","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.164.3.1617","article-title":"Delineation of a CpG phosphorothionate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.","volume":"164","author":"Hartmann","year":"2000","journal-title":"J Immunol"},{"key":"R30-1-20210131","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1016\/S0264-410X(01)00002-0","article-title":"Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian\/human immunodeficiency virus (SHIV89.6P).","volume":"19","author":"Cafaro","year":"2001","journal-title":"Vaccine"},{"key":"R31-1-20210131","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1128\/JVI.77.1.375-381.2003","article-title":"Importance of B cell responses for immunological control of variant strains of simian immunodeficiency virus.","volume":"77","author":"Johnson","year":"2003","journal-title":"J Virol"},{"key":"R32-1-20210131","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1128\/JVI.72.10.7992-8001.1998","article-title":"Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J.","volume":"72","author":"Rossio","year":"1998","journal-title":"Virol"},{"key":"R35-1-20210131","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0684.2005.00128.x","article-title":"Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS.","volume":"34","author":"Cline","year":"2005","journal-title":"J Med Primatol"},{"key":"R36-1-20210131","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1089\/088922299309739","article-title":"Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression.","volume":"15","author":"Smith","year":"1999","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R37-1-20210131","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1128\/JVI.76.14.7187-7202.2002","article-title":"Immunization of rhesus macaques with a DNA prime\/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J.","volume":"76","author":"Horton","year":"2002","journal-title":"Virol"},{"key":"R38-1-20210131","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1128\/JVI.71.7.5069-5079.1997","article-title":"Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency and its association with the development of protective immunity.","volume":"71","author":"Cole","year":"1997","journal-title":"J Virol"},{"key":"R39-1-20210131","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1126\/science.285.5431.1261","article-title":"Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus.","volume":"285","author":"Stahl-Hennig","year":"1999","journal-title":"Science"},{"key":"R40-1-20210131","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/aid.1994.10.351","article-title":"Mucosal infection of neonatal rhesus monkeys with cell-free SIV.","volume":"10","author":"Baba","year":"1994","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R41-1-20210131","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1128\/JVI.71.12.9808-9812.1997","article-title":"Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.","volume":"71","author":"Cao","year":"1997","journal-title":"J Virol"},{"key":"R42-1-20210131","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1128\/jvi.76.5.2075-2086.2002","article-title":"A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.","volume":"76","author":"Johnson","year":"2002","journal-title":"J Virol"},{"key":"R43-1-20210131","doi-asserted-by":"crossref","first-page":"7840","DOI":"10.1128\/JVI.72.10.7840-7845.1998","article-title":"An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.","volume":"72","author":"Stamatatos","year":"1998","journal-title":"J Virol"},{"key":"R44-1-20210131","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1016\/j.vaccine.2007.09.017","article-title":"Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).","volume":"25","author":"Zhou","year":"2007","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"R45-1-20210131","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1080\/13547500500216629","article-title":"Biomarkers and assessment of vaccine responses.","volume":"10","author":"Hogrefe","year":"2005","journal-title":"Biomarkers"},{"key":"R46-1-20210131","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1128\/JVI.76.8.4108-4112.2002","article-title":"Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.","volume":"76","author":"Allen","year":"2002","journal-title":"J Virol"},{"key":"R47-1-20210131","doi-asserted-by":"crossref","first-page":"10507","DOI":"10.1128\/JVI.76.20.10507-10511.2002","article-title":"Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.","volume":"76","author":"Allen","year":"2002","journal-title":"J Virol"},{"key":"R48-1-20210131","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/aid.1994.10.195","article-title":"Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus.","volume":"10","author":"Ahmad","year":"1994","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R49-1-20210131","doi-asserted-by":"crossref","first-page":"10386","DOI":"10.1128\/JVI.79.16.10386-10396.2005","article-title":"Influence of glycosylation on the efficacy of an Env-based vaccine against simian immunodeficiency virus SIVmac239 in a macaque AIDS model.","volume":"79","author":"Mori","year":"2005","journal-title":"J Virol"},{"key":"R50-1-20210131","doi-asserted-by":"crossref","first-page":"15547","DOI":"10.1128\/JVI.79.24.15547-15555.2005","article-title":"Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag.","volume":"79","author":"Casimiro","year":"2005","journal-title":"J Virol"},{"key":"R51-1-20210131","doi-asserted-by":"crossref","first-page":"10199","DOI":"10.1128\/JVI.01103-08","article-title":"Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial.","volume":"82","author":"Kawada","year":"2008","journal-title":"J Virol"},{"key":"R52-1-20210131","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/135965350501000409","article-title":"Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1.","volume":"10","author":"John","year":"2005","journal-title":"Antivir Ther"},{"key":"R53-1-20210131","doi-asserted-by":"crossref","first-page":"9252","DOI":"10.1158\/0008-5472.CAN-06-1239","article-title":"Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy.","volume":"66","author":"Pore","year":"2006","journal-title":"Cancer Res"},{"issue":"9","key":"R54-1-20210131","doi-asserted-by":"crossref","first-page":"e3162","DOI":"10.1371\/journal.pone.0003162","article-title":"Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity.","volume":"3","author":"Turville","year":"2008","journal-title":"PLos ONE"},{"key":"R55-1-20210131","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.4049\/jimmunol.173.7.4433","article-title":"Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells.","volume":"173","author":"Moseman","year":"2004","journal-title":"J Immunol"},{"key":"R56-1-20210131","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1084\/jem.20061660","article-title":"Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand.","volume":"204","author":"Ito","year":"2007","journal-title":"J Exp Med"},{"key":"R57-1-20210131","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1172\/JCI34823","article-title":"HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism.","volume":"118","author":"Manches","year":"2008","journal-title":"J Clin Invest"},{"key":"R58-1-20210131","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1128\/CVI.00471-08","article-title":"Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine.","volume":"16","author":"Wang","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"R59-1-20210131","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1089\/aid.2007.0191","article-title":"DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.","volume":"24","author":"Manrique","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R60-1-20210131","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.vaccine.2007.11.025","article-title":"Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.","volume":"26","author":"Martinon","year":"2008","journal-title":"Vaccine"},{"key":"R61-1-20210131","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1084\/jem.20071211","article-title":"Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus.","volume":"204","author":"Kwissa","year":"2007","journal-title":"J Exp Med"},{"key":"R62-1-20210131","doi-asserted-by":"crossref","first-page":"10911","DOI":"10.1128\/JVI.01129-08","article-title":"Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge.","volume":"82","author":"Demberg","year":"2008","journal-title":"J Virol"},{"key":"R63-1-20210131","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature07469","article-title":"Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.","volume":"457","author":"Liu","year":"2009","journal-title":"Nature"},{"key":"R64-1-20210131","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.1470917","article-title":"Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.","volume":"258","author":"Daniel","year":"1992","journal-title":"Science"},{"key":"R65-1-20210131","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/viro.1996.8419","article-title":"Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa.","volume":"229","author":"Cranage","year":"1997","journal-title":"Virology"},{"key":"R66-1-20210131","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1128\/JVI.00015-08","article-title":"Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery.","volume":"82","author":"Mansfield","year":"2008","journal-title":"J Virol"},{"key":"R67-1-20210131","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1006\/viro.1993.1398","article-title":"Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.","volume":"195","author":"Spear","year":"1993","journal-title":"Virology"},{"key":"R68-1-20210131","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1128\/JVI.77.4.2736-2740.2003","article-title":"Expression of the major histocompatibility complex class I molecule Mamu-A*01 is as01 is associated with control of simian immunodeficiency virus SIVmac239 replication.","volume":"77","author":"Mothe","year":"2003","journal-title":"J Virol"},{"key":"R69-1-20210131","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance.","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"R70-1-20210131","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-4690-3-52","article-title":"Differential susceptibility of naive, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission.","volume":"3","author":"Groot","year":"2006","journal-title":"Retrovirology"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200912010-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T11:33:58Z","timestamp":1685187238000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200912010-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181b880f3","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}